ClinicalTrials.Veeva

Menu
T

The Urology Group | Cincinnati, OH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Androgen
Enobosarm
Darolutamide
GTx-024
Zoledronic Acid
Enzalutamide
TAR-200
Rucaparib
Apalutamide
Toremifene Citrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 33 total trials

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: TAR-200
Biological: Cetrelimab

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive b...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Mitomycin C
Drug: Gemcitabine

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in pa...

Active, not recruiting
Metastatic Hormone-sensitive Prostate Cancer
Other: ADT
Drug: Darolutamide (BAY1841788, Nubeqa)

Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects wi...

Active, not recruiting
Lower Urinary Tract Symptoms
Urinary Bladder, Overactive
Device: INTIBIA Non-Therapeutic
Device: INTIBIA Therapeutic

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants wi...

Enrolling
High-Risk Non-Muscle-Invasive Bladder Cancer
Drug: Cretostimogene Grenadenorepvec

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with G...

Active, not recruiting
Prostate Cancer
Device: Vanquish System

Trial sponsors

G
Bayer logo
Janssen (J&J Innovative Medicine) logo
C
Novartis logo
P
P
AEterna Zentaris logo
Abbott logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems